ibandronic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
calcium metabolism regulator, pharmaceutical aid 1404 114084-78-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • bonviva
  • ibandronic acid
  • ibandronate
  • boniva
  • ibandronate sodium
Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.
  • Molecular weight: 319.23
  • Formula: C9H23NO7P2
  • CLOGP: -1.52
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 5
  • TPSA: 138.53
  • ALOGS: -1.38
  • ROTB: 9
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
5 mg O
6 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 55 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.13 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0.63 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.55 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 1.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.15 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 14 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K2,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPK9,NTRK1,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,SRC,STK33,SYK,TEK,TGFBR1,ULK1,ZAP70 56
kinase-selectivity-class AXL,BRAF,CDK4,CDK9,DDR1,DYRK1B,EPHB4,ERBB2,GRK2,JAK2,MAP2K6,MAP3K14,MAP3K2,MAPK7,MAPK8,PIK3CD,PRKDC,STK33,SYK,TEK,TGFBR1,ZAP70 22
pfas-class PFAS structural alert (1 = True, 0 = False) 0

Approvals:

DateAgencyCompanyOrphan
May 16, 2003 FDA HOFFMANN LA ROCHE
June 25, 1996 EMA Atnahs Pharma Netherlands B.V.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteonecrosis of jaw 1707.47 14.37 566 23778 38537 90565566
Femur fracture 919.21 14.37 375 23969 45707 90558396
Atypical femur fracture 608.13 14.37 169 24175 6252 90597851
Low turnover osteopathy 353.85 14.37 101 24243 4117 90599986
Osteonecrosis 331.54 14.37 155 24189 26086 90578017
Bone pain 317.03 14.37 201 24143 61782 90542321
Exposed bone in jaw 281.52 14.37 78 24266 2848 90601255
Stress fracture 260.45 14.37 95 24249 8516 90595587
Metastases to bone 227.82 14.37 119 24225 25386 90578717
Intramedullary rod insertion 218.65 14.37 60 24284 2112 90601991
Tooth extraction 164.15 14.37 74 24270 11439 90592664
Injection site extravasation 148.04 14.37 64 24280 8955 90595148
Osteomyelitis 146.51 14.37 92 24252 27754 90576349
Pain in jaw 136.79 14.37 109 24235 47876 90556227
Metastases to liver 133.82 14.37 88 24256 28719 90575384
Acute phase reaction 133.09 14.37 28 24316 304 90603799
Fall 118.74 14.37 340 24004 481470 90122633
Myalgia 111.66 14.37 182 24162 174943 90429160
Sequestrectomy 108.97 14.37 28 24316 761 90603342
Back pain 101.65 14.37 247 24097 316928 90287175
Anaemia postoperative 100.17 14.37 33 24311 2180 90601923
Fracture nonunion 99.03 14.37 33 24311 2259 90601844
Fracture displacement 96.08 14.37 28 24316 1228 90602875
Ulna fracture 95.19 14.37 28 24316 1269 90602834
Osteitis 93.56 14.37 36 24308 3737 90600366
Bone disorder 89.24 14.37 63 24281 23057 90581046
Foot fracture 87.94 14.37 66 24278 26540 90577563
Atypical fracture 85.80 14.37 24 24320 907 90603196
Fracture delayed union 84.60 14.37 30 24314 2476 90601627
Maternal exposure during pregnancy 83.48 14.37 3 24341 360060 90244043
Carbohydrate antigen 15-3 increased 83.16 14.37 28 24316 1979 90602124
Actinomycosis 81.08 14.37 24 24320 1112 90602991
Pathological fracture 80.36 14.37 43 24301 9617 90594486
Spinal compression fracture 79.45 14.37 50 24294 15128 90588975
Metastases to pleura 78.74 14.37 27 24317 2017 90602086
Periprosthetic fracture 76.76 14.37 20 24324 575 90603528
Extravasation 76.07 14.37 29 24315 2935 90601168
Fracture 75.72 14.37 56 24288 22020 90582083
Infusion related reaction 73.36 14.37 12 24332 416768 90187335
Vitamin D deficiency 70.46 14.37 49 24295 17507 90586596
Glossodynia 70.28 14.37 4 24340 321775 90282328
Drug ineffective 69.64 14.37 170 24174 1384128 89219975
Pain in extremity 68.96 14.37 271 24073 450258 90153845
Influenza like illness 67.24 14.37 95 24249 80516 90523587
Pelvic fracture 67.06 14.37 45 24299 15174 90588929
Systemic lupus erythematosus 66.95 14.37 9 24335 361887 90242216
Isosthenuria 64.09 14.37 13 24331 116 90603987
Open reduction of fracture 63.52 14.37 20 24324 1142 90602961
Malignant neoplasm progression 62.61 14.37 107 24237 106763 90497340
Metastases to adrenals 62.61 14.37 19 24325 959 90603144
Hepatic enzyme increased 62.12 14.37 11 24333 360725 90243378
Hydrothorax 61.59 14.37 19 24325 1014 90603089
Jaw operation 60.41 14.37 18 24326 853 90603250
Femoral neck fracture 59.38 14.37 36 24308 10197 90593906
Synovitis 59.13 14.37 9 24335 329743 90274360
Spinal fracture 58.46 14.37 48 24296 21968 90582135
Invasive ductal breast carcinoma 57.28 14.37 32 24312 7786 90596317
Oral cavity fistula 56.61 14.37 16 24328 628 90603475
Pyelitis 54.87 14.37 13 24331 250 90603853
Abscess jaw 54.86 14.37 19 24325 1462 90602641
Dental caries 53.36 14.37 35 24309 11362 90592741
Tooth disorder 53.33 14.37 53 24291 31037 90573066
Spinal osteoarthritis 51.37 14.37 42 24302 19106 90584997
Lower respiratory tract infection 49.41 14.37 5 24339 250654 90353449
Fistula 49.12 14.37 34 24310 12055 90592048
Injection site inflammation 48.74 14.37 24 24320 4517 90599586
Metastases to the mediastinum 47.41 14.37 14 24330 643 90603460
Arthralgia 47.36 14.37 364 23980 778158 89825945
Jaw disorder 46.95 14.37 25 24319 5534 90598569
Metastases to spine 46.90 14.37 22 24322 3721 90600382
Treatment failure 46.73 14.37 12 24332 303916 90300187
Joint swelling 46.67 14.37 40 24304 503260 90100843
Bladder hypertrophy 45.71 14.37 13 24331 522 90603581
Electrocardiogram PR shortened 45.57 14.37 13 24331 528 90603575
Metastases to lymph nodes 45.45 14.37 32 24312 11657 90592446
Product use issue 45.34 14.37 16 24328 329903 90274200
Metastases to lung 44.85 14.37 36 24308 15955 90588148
Congenital coronary artery malformation 44.60 14.37 10 24334 149 90603954
Lymphoedema 42.97 14.37 33 24311 13720 90590383
Hyperlipidaemia 42.93 14.37 41 24303 22875 90581228
Polyneuropathy 42.83 14.37 38 24306 19303 90584800
Discomfort 41.85 14.37 11 24333 274324 90329779
Breast cancer recurrent 41.62 14.37 23 24321 5480 90598623
Periodontal disease 41.26 14.37 16 24328 1696 90602407
Drug intolerance 40.96 14.37 36 24308 447555 90156548
Hypophosphataemic osteomalacia 40.06 14.37 10 24334 241 90603862
Groin pain 39.69 14.37 30 24314 12183 90591920
Carcinoembryonic antigen increased 39.62 14.37 17 24327 2333 90601770
Radius fracture 39.35 14.37 20 24324 4024 90600079
Condition aggravated 38.46 14.37 63 24281 595482 90008621
Gingival swelling 38.04 14.37 21 24323 4992 90599111
Rib fracture 38.01 14.37 41 24303 26394 90577709
Arthropathy 37.89 14.37 26 24318 366216 90237887
Metastases to skin 37.80 14.37 16 24328 2124 90601979
Tooth fracture 36.69 14.37 29 24315 12571 90591532
Neutropenia 36.53 14.37 138 24206 224766 90379337
Wound haemorrhage 36.38 14.37 17 24327 2850 90601253
Bone density decreased 36.28 14.37 33 24311 17312 90586791
Muscle injury 36.21 14.37 3 24341 176651 90427452
Gastrooesophageal reflux disease 35.70 14.37 112 24232 166225 90437878
Blister 35.66 14.37 12 24332 254986 90349117
Hypersensitivity 35.43 14.37 42 24302 454635 90149468
Osteopenia 35.42 14.37 37 24307 22965 90581138
Injection site swelling 35.14 14.37 60 24284 59779 90544324
Psoriatic arthropathy 35.12 14.37 9 24335 228326 90375777
Gingivitis 34.93 14.37 25 24319 9344 90594759
Wound 34.82 14.37 19 24325 302961 90301142
Exostosis of jaw 34.70 14.37 13 24331 1254 90602849
Breast cancer metastatic 34.05 14.37 30 24314 15102 90589001
Jaw fistula 33.88 14.37 7 24337 69 90604034
Temporomandibular joint syndrome 33.74 14.37 18 24326 3999 90600104
Bone sequestrum 32.97 14.37 13 24331 1440 90602663
Calcification metastatic 32.62 14.37 8 24336 179 90603924
Nasopharyngitis 32.37 14.37 37 24307 407067 90197036
Device failure 31.85 14.37 21 24323 6876 90597227
PIK3CA-activated mutation 31.69 14.37 12 24332 1192 90602911
Resorption bone increased 31.55 14.37 12 24332 1207 90602896
Renal impairment 31.46 14.37 80 24264 105341 90498762
Thoracic vertebral fracture 31.10 14.37 19 24325 5455 90598648
Off label use 30.98 14.37 172 24172 1102080 89502023
Product use in unapproved indication 30.80 14.37 27 24317 336209 90267894
Osteocalcin decreased 29.64 14.37 6 24338 53 90604050
Wrist fracture 29.35 14.37 28 24316 15596 90588507
Hormone receptor positive HER2 negative breast cancer 28.76 14.37 8 24336 296 90603807
Chromatopsia 28.60 14.37 9 24335 513 90603590
Osteoporosis 28.54 14.37 73 24271 96458 90507645
No adverse event 28.49 14.37 59 24285 67923 90536180
Internal fixation of fracture 28.33 14.37 10 24334 814 90603289
Injury 28.09 14.37 9 24335 197340 90406763
Lumbar vertebral fracture 28.03 14.37 20 24324 7438 90596665
Bone loss 27.52 14.37 15 24329 3477 90600626
Goitre 27.41 14.37 19 24325 6748 90597355
Compression fracture 27.26 14.37 21 24323 8768 90595335
Calcium deficiency 27.04 14.37 11 24333 1322 90602781
Medical device removal 27.04 14.37 11 24333 1322 90602781
Therapeutic product effect decreased 27.01 14.37 21 24323 277550 90326553
Mobility decreased 27.00 14.37 17 24327 250717 90353386
Tonsillectomy 26.00 14.37 10 24334 1037 90603066
Oral mucosal hypertrophy 25.98 14.37 5 24339 33 90604070
Osteoporotic fracture 25.79 14.37 16 24328 4720 90599383
Hypothyroidism 25.74 14.37 49 24295 53078 90551025
Arteriosclerosis 25.39 14.37 22 24322 10831 90593272
Spondylolisthesis 25.36 14.37 15 24329 4060 90600043
Jaw fracture 25.35 14.37 13 24331 2665 90601438
Irritable bowel syndrome 25.34 14.37 12 24332 207436 90396667
Weight increased 25.31 14.37 46 24298 417881 90186222
Arterial thrombosis 25.10 14.37 11 24333 1589 90602514
Endodontic procedure 24.85 14.37 14 24330 3461 90600642
Hip fracture 24.68 14.37 37 24307 33040 90571063
Wheezing 24.47 14.37 17 24327 238063 90366040
Loose tooth 23.88 14.37 14 24330 3729 90600374
Osteomalacia 23.85 14.37 9 24335 886 90603217
Focal segmental glomerulosclerosis 23.56 14.37 11 24333 1840 90602263
Oral pustule 23.54 14.37 5 24339 57 90604046
Tooth avulsion 23.38 14.37 5 24339 59 90604044
Tooth loss 23.32 14.37 18 24326 7536 90596567
Confusional state 22.95 14.37 43 24301 386162 90217941
Sinus arrhythmia 22.85 14.37 10 24334 1439 90602664
Blood loss anaemia 22.60 14.37 20 24324 10120 90593983
Therapeutic product effect incomplete 22.50 14.37 12 24332 193884 90410219
Tibia fracture 22.13 14.37 16 24328 6071 90598032
Cataract operation 21.96 14.37 16 24328 6147 90597956
Peri-implantitis 21.91 14.37 5 24339 81 90604022
Pancreatic steatosis 21.65 14.37 10 24334 1632 90602471
Humerus fracture 21.22 14.37 19 24325 9766 90594337
Oesophageal stenosis 20.99 14.37 13 24331 3823 90600280
Mediastinal disorder 20.85 14.37 7 24337 490 90603613
Fibromyalgia 20.84 14.37 15 24329 206254 90397849
Injection site erythema 20.82 14.37 66 24278 98436 90505667
Fractured sacrum 20.74 14.37 11 24333 2416 90601687
Abdominal discomfort 20.54 14.37 63 24281 477265 90126838
Erysipelas 20.47 14.37 18 24326 9034 90595069
Dental implantation 20.33 14.37 8 24336 881 90603222
Type 2 diabetes mellitus 20.25 14.37 15 24329 203229 90400874
Creatinine renal clearance increased 20.22 14.37 12 24332 3269 90600834
Oesophagitis 20.12 14.37 24 24320 17225 90586878
Blood bilirubin abnormal 19.95 14.37 10 24334 1954 90602149
Hypercalcaemia 19.66 14.37 34 24310 34206 90569897
Eye opacity 19.59 14.37 3 24341 3 90604100
Gastrointestinal tract irritation 19.27 14.37 7 24337 619 90603484
Ill-defined disorder 19.27 14.37 13 24331 184878 90419225
Ovarian cancer stage III 19.19 14.37 6 24338 335 90603768
Peritoneal disorder 19.07 14.37 7 24337 638 90603465
Chronic hepatic failure 18.92 14.37 7 24337 652 90603451
Upper limb fracture 18.83 14.37 26 24318 21552 90582551
Serratia infection 18.79 14.37 8 24336 1077 90603026
Purulence 18.65 14.37 9 24335 1620 90602483
Renal cyst 18.47 14.37 20 24324 12930 90591173
Infusion site extravasation 18.44 14.37 18 24326 10310 90593793
Bone metabolism disorder 17.83 14.37 6 24338 423 90603680
Osteodystrophy 17.77 14.37 3 24341 8 90604095
Chest wall tumour 17.75 14.37 4 24340 61 90604042
Rheumatoid arthritis 17.71 14.37 45 24299 362569 90241534
Osteochondrosis 17.60 14.37 9 24335 1834 90602269
Urticaria 17.55 14.37 36 24308 312698 90291405
Cellulitis 17.33 14.37 59 24285 91278 90512825
Toxicity to various agents 17.13 14.37 32 24312 287814 90316289
Osteoarthritis 16.91 14.37 100 24244 195630 90408473
Limb asymmetry 16.89 14.37 7 24337 882 90603221
Rhinoplasty 16.84 14.37 3 24341 12 90604091
Scoliosis 16.80 14.37 16 24328 8891 90595212
Pleural effusion 16.76 14.37 67 24277 111924 90492179
Oral neoplasm 16.55 14.37 4 24340 84 90604019
Mucosal inflammation 16.43 14.37 43 24301 57582 90546521
Sinusitis 16.43 14.37 43 24301 343045 90261058
Night sweats 16.42 14.37 7 24337 128759 90475344
Fatigue 16.14 14.37 216 24128 1153807 89450296
Tendon calcification 16.12 14.37 4 24340 94 90604009
Blood alkaline phosphatase decreased 16.05 14.37 8 24336 1545 90602558
Periodontitis 16.04 14.37 11 24333 3842 90600261
X-ray of pelvis and hip abnormal 15.98 14.37 3 24341 17 90604086
Bone graft 15.96 14.37 7 24337 1013 90603090
Bone marrow disorder 15.90 14.37 10 24334 3022 90601081
Dysphagia 15.87 14.37 66 24278 112212 90491891
Intentional product use issue 15.86 14.37 21 24323 216871 90387232
Induration 15.79 14.37 8 24336 1599 90602504
Empyema 15.73 14.37 9 24335 2291 90601812
Neuromuscular toxicity 15.70 14.37 5 24339 296 90603807
Hydronephrosis 15.70 14.37 18 24326 12384 90591719
Glomerular filtration rate decreased 15.68 14.37 21 24323 16911 90587192
Ankle fracture 15.50 14.37 23 24321 20347 90583756
Macular scar 15.42 14.37 4 24340 113 90603990
Dermatitis 15.37 14.37 24 24320 22196 90581907
Phlebitis 15.27 14.37 14 24330 7416 90596687
Administration site induration 15.20 14.37 3 24341 23 90604080
Dental restoration failure 15.07 14.37 7 24337 1157 90602946
Hyperparathyroidism 15.02 14.37 10 24334 3327 90600776
Eczema asteatotic 14.98 14.37 5 24339 344 90603759
Oral dysaesthesia 14.97 14.37 4 24340 127 90603976
Fibrocystic breast disease 14.79 14.37 7 24337 1207 90602896
Blood parathyroid hormone increased 14.75 14.37 10 24334 3427 90600676
Prescribed overdose 14.71 14.37 4 24340 97621 90506482
Past-pointing 14.71 14.37 4 24340 136 90603967
Gastrointestinal mucosal exfoliation 14.71 14.37 4 24340 136 90603967
Dental necrosis 14.62 14.37 4 24340 139 90603964
Hot flush 14.58 14.37 42 24302 59446 90544657
Dorsal ramus syndrome 14.51 14.37 4 24340 143 90603960
Lumbar spinal stenosis 14.43 14.37 12 24332 5585 90598518
Dental care 14.40 14.37 7 24337 1281 90602822

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteonecrosis of jaw 170.29 25.22 53 1755 18996 42600531
Osteonecrosis 66.21 25.22 25 1783 15840 42603687
Rectal polyp 47.92 25.22 10 1798 714 42618813
Jaw fracture 43.89 25.22 10 1798 1074 42618453
Appetite disorder 42.66 25.22 12 1796 3003 42616524
Femur fracture 32.20 25.22 13 1795 9799 42609728
Fall 30.20 25.22 43 1765 234477 42385050
Foot fracture 26.69 25.22 10 1798 6181 42613346

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteonecrosis of jaw 1710.29 15.38 528 17526 47489 110523756
Atypical femur fracture 600.95 15.38 150 17904 6069 110565176
Femur fracture 494.90 15.38 207 17847 44262 110526983
Osteonecrosis 351.75 15.38 150 17904 33591 110537654
Exposed bone in jaw 266.10 15.38 71 17983 3740 110567505
Bone pain 206.49 15.38 130 17924 65003 110506242
Stress fracture 142.38 15.38 51 18003 7170 110564075
Pain in jaw 139.66 15.38 93 17961 51084 110520161
Osteomyelitis 138.90 15.38 82 17972 36518 110534727
Metastases to bone 134.25 15.38 76 17978 31296 110539949
Tooth extraction 129.52 15.38 56 17998 12935 110558310
Acute phase reaction 125.07 15.38 26 18028 453 110570792
Sequestrectomy 121.22 15.38 28 18026 808 110570437
Injection site extravasation 108.52 15.38 46 18008 10123 110561122
Osteitis 106.51 15.38 36 18018 4260 110566985
Actinomycosis 98.46 15.38 26 18028 1314 110569931
Fall 96.50 15.38 265 17789 603217 109968028
Atypical fracture 94.74 15.38 24 18030 1028 110570217
Ulna fracture 85.74 15.38 23 18031 1235 110570010
Fracture displacement 82.17 15.38 23 18031 1449 110569796
Myalgia 80.20 15.38 136 17918 222245 110349000
Carbohydrate antigen 15-3 increased 75.99 15.38 22 18032 1565 110569680
Fracture 72.35 15.38 47 18007 24741 110546504
Pathological fracture 70.70 15.38 36 18018 11996 110559249
Hydrothorax 70.66 15.38 21 18033 1637 110569608
Isosthenuria 70.26 15.38 13 18041 119 110571126
Jaw operation 69.85 15.38 18 18036 826 110570419
Bone disorder 68.86 15.38 43 18011 21149 110550096
Oral cavity fistula 63.49 15.38 16 18038 671 110570574
Femoral neck fracture 57.98 15.38 32 18022 12535 110558710
Breast cancer recurrent 56.88 15.38 22 18032 3824 110567421
Spinal compression fracture 56.46 15.38 36 18018 18356 110552889
Electrocardiogram PR shortened 56.22 15.38 13 18041 377 110570868
Pyelitis 55.01 15.38 13 18041 415 110570830
Arthralgia 54.22 15.38 261 17793 779371 109791874
Pain in extremity 52.74 15.38 187 17867 486931 110084314
Back pain 52.41 15.38 156 17898 370840 110200405
Congenital coronary artery malformation 51.81 15.38 10 18044 117 110571128
Foot fracture 50.17 15.38 38 18016 25508 110545737
Metastases to lymph nodes 50.10 15.38 31 18023 15001 110556244
Bone sequestrum 49.87 15.38 15 18039 1218 110570027
Amaurosis fugax 47.56 15.38 17 18037 2373 110568872
Fistula 47.10 15.38 30 18024 15269 110555976
Influenza like illness 45.82 15.38 64 17990 88348 110482897
Fracture delayed union 45.10 15.38 16 18038 2185 110569060
Carcinoembryonic antigen increased 44.80 15.38 17 18037 2807 110568438
Groin pain 44.40 15.38 29 18025 15399 110555846
Spinal fracture 42.97 15.38 33 18021 22600 110548645
Drug ineffective 42.95 15.38 118 17936 1520422 109050823
Lymphoedema 42.81 15.38 28 18026 14901 110556344
Periprosthetic fracture 42.73 15.38 12 18042 765 110570480
Bladder hypertrophy 42.58 15.38 13 18041 1111 110570134
Abscess jaw 40.29 15.38 14 18040 1800 110569445
Hypophosphataemic osteomalacia 39.50 15.38 10 18044 427 110570818
Jaw fracture 39.49 15.38 16 18038 3140 110568105
Injection site inflammation 39.31 15.38 18 18036 4753 110566492
Low turnover osteopathy 38.80 15.38 14 18040 2008 110569237
Calcification metastatic 38.08 15.38 8 18046 147 110571098
Metastases to liver 37.52 15.38 37 18017 35349 110535896
Gingival swelling 37.41 15.38 18 18036 5312 110565933
Pelvic fracture 36.86 15.38 25 18029 14129 110557116
Dental caries 36.74 15.38 24 18030 12749 110558496
Wound haemorrhage 36.31 15.38 17 18037 4721 110566524
Gingivitis 36.20 15.38 22 18032 10309 110560936
Extravasation 35.95 15.38 17 18037 4828 110566417
Hormone receptor positive HER2 negative breast cancer 34.40 15.38 8 18046 238 110571007
Jaw fistula 32.71 15.38 7 18047 141 110571104
Pancreatic steatosis 32.67 15.38 12 18042 1810 110569435
Infusion related reaction 32.24 15.38 11 18043 381151 110190094
Tooth disorder 31.55 15.38 31 18023 29478 110541767
Resorption bone increased 30.86 15.38 11 18043 1523 110569722
Lumbar vertebral fracture 30.86 15.38 19 18035 9112 110562133
Thoracic vertebral fracture 30.85 15.38 17 18037 6638 110564607
Maternal exposure during pregnancy 30.76 15.38 3 18051 254880 110316365
Metastases to lung 29.97 15.38 27 18027 23036 110548209
Hepatic enzyme increased 29.41 15.38 8 18046 320884 110250361
Metastases to the mediastinum 29.31 15.38 9 18045 784 110570461
Jaw disorder 28.90 15.38 15 18039 5197 110566048
Osteoporotic fracture 28.56 15.38 15 18039 5322 110565923
Oral mucosal hypertrophy 28.34 15.38 5 18049 34 110571211
Injection site swelling 28.02 15.38 42 18012 61748 110509497
Metastases to pleura 27.69 15.38 11 18043 2052 110569193
Urinary tract disorder 27.29 15.38 15 18039 5829 110565416
Synovitis 26.73 15.38 6 18048 274086 110297159
Osteocalcin decreased 26.62 15.38 5 18049 50 110571195
Lower respiratory tract infection 26.54 15.38 4 18050 243102 110328143
Neutropenia 26.35 15.38 126 17928 374494 110196751
Oesophageal stenosis 26.18 15.38 14 18040 5151 110566094
Systemic lupus erythematosus 25.98 15.38 5 18049 254333 110316912
Compression fracture 25.59 15.38 17 18037 9282 110561963
Exostosis of jaw 25.39 15.38 9 18045 1226 110570019
Creatinine renal clearance increased 24.71 15.38 12 18042 3613 110567632
Tooth fracture 24.56 15.38 19 18035 13148 110558097
Ocular discomfort 24.46 15.38 16 18038 8517 110562728
Infusion site extravasation 24.39 15.38 18 18036 11616 110559629
Fractured sacrum 24.38 15.38 10 18044 2026 110569219
Temporomandibular joint syndrome 23.97 15.38 12 18042 3857 110567388
Toxicity to various agents 23.81 15.38 26 18028 480529 110090716
Sinus arrhythmia 23.76 15.38 10 18044 2160 110569085
Dorsal ramus syndrome 23.72 15.38 4 18050 20 110571225
Glossodynia 23.46 15.38 4 18050 222000 110349245
Treatment failure 23.43 15.38 8 18046 277226 110294019
Arterial thrombosis 23.31 15.38 11 18043 3108 110568137
Pain 23.26 15.38 248 17806 954707 109616538
Arthropathy 23.11 15.38 9 18045 287513 110283732
Purulence 23.09 15.38 10 18044 2317 110568928
Ovarian cancer stage III 22.98 15.38 6 18048 290 110570955
Tooth avulsion 22.94 15.38 5 18049 110 110571135
Mucosal ulceration 22.88 15.38 10 18044 2369 110568876
Loose tooth 22.87 15.38 11 18043 3242 110568003
Induration 22.83 15.38 10 18044 2379 110568866
Drug intolerance 21.26 15.38 21 18033 406491 110164754
Periodontal disease 21.08 15.38 9 18045 2013 110569232
Injection site erythema 20.92 15.38 47 18007 94129 110477116
Peritoneal disorder 20.78 15.38 7 18047 819 110570426
Focal segmental glomerulosclerosis 20.35 15.38 11 18043 4134 110567111
Bone lesion excision 20.33 15.38 4 18050 52 110571193
Hypercalcaemia 20.14 15.38 31 18023 46626 110524619
Blood parathyroid hormone increased 20.10 15.38 11 18043 4237 110567008
Renal impairment 20.03 15.38 72 17982 188373 110382872
Peri-implantitis 19.83 15.38 5 18049 210 110571035
Chest wall tumour 19.80 15.38 4 18050 60 110571185
Joint swelling 19.77 15.38 26 18028 442819 110128426
Haemorrhagic stroke 19.63 15.38 17 18037 13772 110557473
Bone density decreased 19.32 15.38 18 18036 16024 110555221
Intramedullary rod insertion 19.29 15.38 5 18049 235 110571010
Head discomfort 18.55 15.38 19 18035 18981 110552264
Open reduction of fracture 18.42 15.38 5 18049 281 110570964
Off label use 18.32 15.38 157 17897 1500028 109071217
Chronic hepatic failure 17.84 15.38 7 18047 1264 110569981
Condition aggravated 17.81 15.38 61 17993 734775 109836470
Macular scar 17.79 15.38 4 18050 102 110571143
X-ray of pelvis and hip abnormal 17.79 15.38 3 18051 15 110571230
Product use in unapproved indication 17.30 15.38 29 18025 447348 110123897
Eye opacity 17.05 15.38 3 18051 20 110571225
Serratia infection 16.99 15.38 8 18046 2251 110568994
Occupational exposure to product 16.82 15.38 6 18048 833 110570412
Hypotension 16.76 15.38 38 18016 523811 110047434
Hypersensitivity 16.75 15.38 25 18029 403973 110167272
Neuromuscular toxicity 16.50 15.38 5 18049 416 110570829
Blood alkaline phosphatase decreased 16.36 15.38 8 18046 2445 110568800
Osteomalacia 16.34 15.38 7 18047 1580 110569665
Past-pointing 16.23 15.38 4 18050 153 110571092
Fibromyalgia 16.15 15.38 4 18050 170905 110400340
Hip fracture 16.09 15.38 24 18030 35127 110536118
Confusional state 15.81 15.38 33 18021 468647 110102598
Periodontitis 15.50 15.38 10 18044 5198 110566047
Blister 15.39 15.38 9 18045 227367 110343878

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC M05BA06 MUSCULO-SKELETAL SYSTEM
DRUGS FOR TREATMENT OF BONE DISEASES
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
Bisphosphonates
ATC M05BB09 MUSCULO-SKELETAL SYSTEM
DRUGS FOR TREATMENT OF BONE DISEASES
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
Bisphosphonates, combinations
FDA CS M0006519 Diphosphonates
FDA EPC N0000175579 Bisphosphonate
MeSH PA D050071 Bone Density Conservation Agents
CHEBI has role CHEBI:35480 analgesic
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:50646 bone density conservation agent
CHEBI has role CHEBI:73336 vulnerary

Related Drugs by ATC class:

M05BA Bisphosphonates 7 drugs
alendronic acidclodronic acidetidronic acidpamidronic acidrisedronic acidtiludronic acidzoledronic acid
M05BB Bisphosphonates, combinations 6 drugs
alendronic acidalfacalcidolcolecalciferoletidronic acidrisedronic acidzoledronic acid

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Hypercalcemia indication 66931009 DOID:12678
Postmenopausal osteoporosis indication 102447009
Gastritis contraindication 4556007 DOID:4029
Hypocalcemia contraindication 5291005
Bone pain contraindication 12584003
Heartburn contraindication 16331000
Esophagitis contraindication 16761005 DOID:11963
Swallowing painful contraindication 30233002
Ulcer of esophagus contraindication 30811009
Vitamin D deficiency contraindication 34713006
Dysphagia contraindication 40739000
Achalasia of esophagus contraindication 45564002 DOID:9164
Joint pain contraindication 57676002
Acute nephropathy contraindication 58574008
Stricture of esophagus contraindication 63305008
Muscle pain contraindication 68962001
Fracture of femur contraindication 71620000
Duodenitis contraindication 72007001 DOID:8643
Bed-ridden contraindication 160685001
Acute peptic ulcer contraindication 196682000
Tooth disorder contraindication 234947003 DOID:1091
Esophageal dysmotility contraindication 266434009 DOID:9192
Primary malignant neoplasm contraindication 372087000
Aseptic necrosis of bone of jaw contraindication 441809006
Invasive Dental Procedure contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.98 acidic
pKa2 4.97 acidic
pKa3 9.03 acidic
pKa4 13.3 acidic
pKa5 7.94 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Farnesyl pyrophosphate synthase Enzyme INHIBITOR Ki 8.44 CHEMBL CHEMBL
Geranylgeranyl pyrophosphate synthase Enzyme IC50 4.10 CHEMBL
Squalene synthase Enzyme IC50 6.19 CHEMBL
Farnesyl pyrophosphate synthase Enzyme INHIBITOR IC50 5.13 IUPHAR

External reference:

IDSource
D08056 KEGG_DRUG
138926-19-9 SECONDARY_CAS_RN
4021407 VANDF
C0379200 UMLSCUI
BFQ PDB_CHEM_ID
CHEMBL997 ChEMBL_ID
CHEMBL3989569 ChEMBL_ID
DB00710 DRUGBANK_ID
D000077557 MESH_DESCRIPTOR_UI
60852 PUBCHEM_CID
3059 IUPHAR_LIGAND_ID
7189 INN_ID
UMD7G2653W UNII
115264 RXNORM
188271 MMSL
67270 MMSL
d05357 MMSL
007178 NDDF
007179 NDDF
395271007 SNOMEDCT_US
404839003 SNOMEDCT_US
420936009 SNOMEDCT_US
96287002 SNOMEDCT_US
CHEBI:41060 CHEBI

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ibandronate Sodium HUMAN PRESCRIPTION DRUG LABEL 1 16729-274 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 29 sections
IBANDRONATE SODIUM Human Prescription Drug Label 1 33342-150 TABLET, FILM COATED 150 mg ORAL ANDA 28 sections
Ibandronate sodium HUMAN PRESCRIPTION DRUG LABEL 1 50090-7654 TABLET 150 mg ORAL ANDA 25 sections
Boniva HUMAN PRESCRIPTION DRUG LABEL 1 54868-5322 TABLET, FILM COATED 150 mg ORAL NDA 28 sections
Ibandronate sodium HUMAN PRESCRIPTION DRUG LABEL 1 55111-575 TABLET 150 mg ORAL ANDA 27 sections
Ibandronate Sodium Human Prescription Drug Label 1 55150-191 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 28 sections
IBANDRONATE SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 60429-643 TABLET, FILM COATED 150 mg ORAL ANDA 29 sections
IBANDRONATE SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 60505-2795 TABLET, FILM COATED 150 mg ORAL ANDA 29 sections
IBANDRONATE SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 60505-2795 TABLET, FILM COATED 150 mg ORAL ANDA 29 sections
Ibandronate Sodium HUMAN PRESCRIPTION DRUG LABEL 1 60505-6097 INJECTION 3 mg INTRAVENOUS ANDA 29 sections
Ibandronate Sodium HUMAN PRESCRIPTION DRUG LABEL 1 60505-6097 INJECTION 3 mg INTRAVENOUS ANDA 29 sections
IBANDRONATE SODIUM Human Prescription Drug Label 1 62756-218 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 28 sections
Ibandronate Sodium Human Prescription Drug Label 1 65862-237 TABLET, FILM COATED 150 mg ORAL ANDA 28 sections
IBANDRONATE SODIUM HUMAN PRESCRIPTION DRUG LABEL 1 69452-378 TABLET 150 mg ORAL ANDA 27 sections